The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review
Open accessAbstract
BACKGROUND & AIMS: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues. METHODS: We performed a literature search to identify studies with chronic hepatitis B patients treated with nucleos(t)ide analogues for> or = 24 months. RESULTS: Twenty-one studies including 3881 treated and 534 untreated patients met our inclusion criteria. HCC was diagnosed in 2.8% and 6.4% of treated and untreated patients, respectively, during a 46 (32-108) month period (p=0.003), in 10.8% and 0.5% of nucleos(t)ide naive patients with and without cirrhosis (p<0.001) and in 17.6% and 0% of lamivudine resistance patients with and without cirrhosis (p<0.001). HCC developed less frequently in nucleos(t)ide naive patients compared to those without virological remission (2.3% vs 7.5%, p<0.001), but there was no difference between lamivudine resistance patients with or without virological response to rescue therapy (5.9% vs 8.8%, p=0.466). CONCLUSIONS: Chronic hepatitis B patients receiving medium-term nucleos(t)ide analogue therapy had a significantly lower incidence of HCC compared to untreated patients but treatment does not completely eliminate the risk of HCC. Among the treated patients, cirrhosis, HBeAg negative at baseline and failure to remain in virological remission were associated with an increased risk of HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Self-citationRising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Panahi, M., Naderi, M., Morteza, T. S., & Parizadeh, S. M. J. (2007) · Cited by 1,722
EASL clinical practice guidelines management of chronic hepatitis B
张学武, & Li, X. (2009) · Inter J Epidemiol Infect Dis · doi:10.3760/cma.j.issn.1673-4149.2009.04.001 · Cited by 1,506
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.001 · Cited by 1,347
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.020 · Cited by 881
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
Lok, A. S. F., Lai, C.-L., Leung, N., Yao, G.-B., Cui, Z.-Y., Schiff, E. R., Dienstag, J. L., Heathcote, E. J., Little, N. R., Griffiths, D. A., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.033 · Cited by 764
Self-citation
Cited by
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & El‐Serag, H. B. (2021) · Hepatology · doi:10.1002/hep.31288 · Cited by 2,147
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61097-0 · Cited by 1,267
Epidemiology and surveillance for hepatocellular carcinoma: New trends
Singal, A. G., Lampertico, P., & Nahon, P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.025 · Cited by 1,102
Self-citationMechanisms of HBV-induced hepatocellular carcinoma
Levrero, M., & Zucman-Rossi, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.021 · Cited by 1,052
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
Arzumanyan, A., Reis, H. M. G. P. V., & Feitelson, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3449 · Cited by 800
Hosaka, T., Suzuki, F., Kobayashi, M., Seko, Y., Kawamura, Y., Sezaki, H., Akuta, N., Suzuki, Y., Saitoh, S., Arase, Y., et al. (2013) · Hepatology · doi:10.1002/hep.26180 · Cited by 710
Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648
Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
El-Serag, H. B., & Kanwal, F. (2014) · Hepatology · doi:10.1002/hep.27222 · Cited by 646
Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., Calleja, J. L., Chi, H., Manolakopoulos, S., Mangia, G., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.035 · Cited by 557
Self-citationHepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice
Singal, A. G., & El-Serag, H. B. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.08.014 · Cited by 530
Papatheodoridis, G. V., Chan, H. L.-Y., Hansen, B. E., Janssen, H. L. A., & Lampertico, P. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.002 · Cited by 511
Self-citationEASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Lai-Hung Wong, G., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 437
Self-citationViral hepatitis and liver cancer
Ringehan, M., McKeating, J. A., & Protzer, U. (2017) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0274 · Cited by 410
Requirements for global elimination of hepatitis B: a modelling study
Nayagam, S., Thursz, M., Sicuri, E., Conteh, L., Wiktor, S., Low-Beer, D., & Hallett, T. B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30204-3 · Cited by 373
Hepatitis B Virus Epidemiology
MacLachlan, J. H., & Cowie, B. C. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021410 · Cited by 339
Wu, C.-Y., Lin, J.-T., Ho, H. J., Su, C.-W., Lee, T.-Y., Wang, S.-Y., Wu, C., & Wu, J.-C. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.048 · Cited by 319
Yip, T. C.-F., Wong, G. L.-H., Chan, H. L.-Y., Tse, Y.-K., Lam, K. L.-Y., Lui, G. C.-Y., & Wong, V. W.-S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.014 · Cited by 318
Degenhardt, L., Charlson, F., Stanaway, J., Larney, S., Alexander, L. T., Hickman, M., Cowie, B., Hall, W. D., Strang, J., Whiteford, H., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30325-5 · Cited by 305
Papatheodoridis, G. V., Idilman, R., Dalekos, G. N., Buti, M., Chi, H., van Boemmel, F., Calleja, J. L., Sypsa, V., Goulis, J., Manolakopoulos, S., et al. (2017) · Hepatology · doi:10.1002/hep.29320 · Cited by 301
Self-citationHepatitis B virus PreS/S gene variants: Pathobiology and clinical implications
Pollicino, T., Cacciola, I., Saffioti, F., & Raimondo, G. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.041 · Cited by 277
Chemopreventive strategies in hepatocellular carcinoma
Singh, S., Singh, P. P., Roberts, L. R., & Sanchez, W. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.143 · Cited by 273
HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment
Singh, K. P., Crane, M., Audsley, J., Avihingsanon, A., Sasadeusz, J., & Lewin, S. R. (2017) · AIDS · doi:10.1097/qad.0000000000001574 · Cited by 268
Lin, C.-W., Lin, C.-C., Mo, L.-R., Chang, C.-Y., Perng, D.-S., Hsu, C.-C., Lo, G.-H., Chen, Y.-S., Yen, Y.-C., Hu, J.-T., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.045 · Cited by 174
Metadata
- Authors
- Papatheodoridis, G. V., Lampertico, P., Manolakopoulos, S., & Lok, A.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 53
- Issue
- 2
- Pages
- 348-356
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2088305891
- Cited by
- 459
- References
- 29
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.